日韩亚洲一区中文字幕在线,欧美中文字幕无线码视频,亚洲欧美中文日韩二区一区,国产专区日韩精品欧美色,欧美国产日本精品一区二区三区|亚洲国产精品久久无码,欧美日韩综合中文字幕不卡三区,欧美日产精品一级免费

阿聯(lián)酋衛(wèi)生和預防部宣布正式注冊“為了人類”臨床試驗項目新冠滅活疫苗
發(fā)布時間:2020-12-10

UAE Ministry of Health and Prevention announces official registration of inactivated COVID-19 vaccine used in #4Humanity Trials

The registration of this vaccine is a decision in response to the application from Sinopharm CNBG. The announcement is a significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.

MOHAP, in collaboration with Department of Health Abu Dhabi, DOH, has reviewed Sinopharm CNBG’s interim analysis of the phase III trials, which shows Beijing Institute of Biological Product’s inactivated vaccine to have 86 percent efficacy against COVID-19 infection. The analysis also shows the vaccine to have 99 percent seroconversion rate of neutralising antibody and 100 percent effectiveness in preventing moderate and severe cases of the disease. Furthermore, the analysis shows no serious safety concerns.

This vaccine was granted Emergency Use Authorisation, EUA, since September by MOHAP to protect frontline workers most at risk of COVID-19. The UAE is conducting Post Authorisation Safety Study, PASS, and Post Authorisation Efficacy Study, PAES, of its EUA programme. These ongoing studies show similar safety and efficacy profiles as the interim analysis.

The #4Humanity phase III trials have included 31,000 volunteers across 125 nationalities in the UAE alone. The EUA vaccination programme has effectively safeguarded the UAE frontline workers. MOHAP's official registration of Beijing Institute of Biological Product’s inactivated COVID-19 vaccine leads the way to comprehensively protecting the population and responsibly opening the economy.

地址:北京市海淀區(qū)知春路20號 中國醫(yī)藥大廈

郵編:100191

電話:86-10-82287727

傳真:86-10-62033332

阿聯(lián)酋衛(wèi)生和預防部宣布正式注冊“為了人類”臨床試驗項目新冠滅活疫苗
發(fā)布時間:2020-12-10

UAE Ministry of Health and Prevention announces official registration of inactivated COVID-19 vaccine used in #4Humanity Trials

The registration of this vaccine is a decision in response to the application from Sinopharm CNBG. The announcement is a significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.

MOHAP, in collaboration with Department of Health Abu Dhabi, DOH, has reviewed Sinopharm CNBG’s interim analysis of the phase III trials, which shows Beijing Institute of Biological Product’s inactivated vaccine to have 86 percent efficacy against COVID-19 infection. The analysis also shows the vaccine to have 99 percent seroconversion rate of neutralising antibody and 100 percent effectiveness in preventing moderate and severe cases of the disease. Furthermore, the analysis shows no serious safety concerns.

This vaccine was granted Emergency Use Authorisation, EUA, since September by MOHAP to protect frontline workers most at risk of COVID-19. The UAE is conducting Post Authorisation Safety Study, PASS, and Post Authorisation Efficacy Study, PAES, of its EUA programme. These ongoing studies show similar safety and efficacy profiles as the interim analysis.

The #4Humanity phase III trials have included 31,000 volunteers across 125 nationalities in the UAE alone. The EUA vaccination programme has effectively safeguarded the UAE frontline workers. MOHAP's official registration of Beijing Institute of Biological Product’s inactivated COVID-19 vaccine leads the way to comprehensively protecting the population and responsibly opening the economy.

地址:北京市海淀區(qū)知春路20號 中國醫(yī)藥大廈

郵編:100191 電話:86-10-82287727

傳真:86-10-62033332

永修县| 即墨市| 柞水县| 确山县| 昔阳县| 清新县| 伊宁市| 赣榆县| 绥滨县| 武安市| 永仁县| 广宁县| 大石桥市| 库伦旗| 五指山市| 彰武县| 新干县| 黎城县| 鲁山县| 迁西县| 余姚市| 岚皋县| 兰溪市| 广南县| 滨海县| 钦州市| 高阳县| 如东县| 彭泽县| 枣庄市| 高青县| 普陀区| 株洲县| 安西县| 张北县| 龙江县| 育儿| 锡林浩特市| 内乡县| 弥勒县| 新宁县|